BBI Group
The deal
Investing in a trusted partner to the world’s leading diagnostic and healthcare organisations
Undisclosed
Deal size, November 2015 & June 2020
Funds III & IV
Realised investment
The story
BBI Group offers a portfolio of products and services that are delivered to the diagnostic and life sciences industries globally. The business has sites in seven countries and four continents. A global team of over 500 experts provides critical reagents and immunoassay development and manufacturing services to a blue chip customer base that includes Thermo-Fisher, Merck and Siemens.
The company was acquired from Alere, a US publicly-listed healthcare business. Exponent worked alongside our Operating Chairperson Alan Peterson, to build the buy-out plan with BBI’s management team.
During our ownership, BBI expanded its presence in the US, built operations in China, successfully completed three acquisitions, consolidated its global production footprint into six state-of-the-art facilities and invested in a centre of excellence at its HQ in Crumlin, Wales.
In June 2021, the business completed the disposal of the non-core BBI Healthcare division to Venture Life Group.
BBI Solutions, was later sold from Exponent Fund III and Exponent Fund IV to Novo Holdings in August 2021.